As of Mar 23
| +0.15 / +0.92%|
The 9 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 17.00, with a high estimate of 28.00 and a low estimate of 13.00. The median estimate represents a +3.03% increase from the last price of 16.50.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.